TempraMed Announces Additional Granted Brazilian Patent for Newest VIVI Box Product

• On 2026‑04‑07 TempraMed announced that the Brazilian Patent Office granted patent No. BR 112021006921‑6 covering core innovations of the upcoming VIVI Box™ multi‑medication storage platform.
• The patent protects thermal‑insulation architecture, continuous temperature protection during power interruptions, portable all‑day cold storage, and cloud‑based smart content tracking.
• Term runs to 23 Oct 2039, supporting the planned market launch of VIVI Box at the end of 2026.
• The grant strengthens TempraMed’s IP position in Brazil, a large diabetes and temperature‑sensitive medication market, and underpins its commercialization strategy with appliance manufacturers across Latin America.

• The announcement is an incremental positive update to the company’s intellectual property portfolio.
• No immediate financial impact (no revenue, no change in cash flow) is disclosed; VIVI Box launch remains scheduled for later 2026.
• The news aligns with TempraMed’s ongoing global IP strategy and prior patent grants (China, South Korea, etc.), thus it is routine rather than unexpected or market‑moving.
• Consequently the materiality assessment is Routine‑Positive, consistent with the rating above.

TempraMed Technologies Ltd. develops battery‑free, temperature‑controlled medication storage solutions for insulin, GLP‑1 agonists, biologics, epinephrine auto‑injectors and other temperature‑sensitive drugs. Core product lines include VIVI Cap, VIVI Cap Smart (digital health add‑on), VIVI Epi, VIVI Med (for vials/biologics) and the forthcoming flagship VIVI Box™ multi‑medication storage platform featuring patented passive thermal insulation and smart cloud‑based monitoring. The company leverages a growing global IP portfolio (granted patents in the US, China, South Korea, Brazil, etc.) and pursues institutional, retail and B2B distribution channels across North America, Europe, Israel and Asia.